Literature DB >> 1370661

Evidence for continuous stimulation of interleukin-6 production in Crohn's disease.

V Gross1, T Andus, I Caesar, M Roth, J Schölmerich.   

Abstract

Increased serum concentrations of acute-phase proteins can be found in active inflammatory bowel disease. Because interleukin 6 (IL-6) is one of the main mediators of acute-phase protein synthesis by the liver, the serum concentrations of IL-6 and the acute-phase proteins C-reactive protein, alpha 1-antitrypsin, and alpha 1-acid glycoprotein were determined in 70 patients with Crohn's disease (CD) and 23 patients with ulcerative colitis (UC). Disease activities were determined by established clinical activity indices. Serum IL-6 concentrations were significantly (P less than 0.005) increased in patients with CD (mean +/- SEM, 6.8 +/- 0.9 U/mL) compared with patients with UC (mean, less than 4 U/mL) and healthy controls (mean, less than 4 U/mL). Of patients with CD, 68.5% had serum IL-6 concentrations of greater than or equal to 4 U/mL, compared with 21.7% of patients with UC and 0% of healthy controls. There was a tendency toward higher serum IL-6 concentrations in patients with active CD than in patients with inactive disease. However, these differences were not statistically significant. There was no correlation between IL-6 serum concentrations and clinical activity indices, possibly because of the short circulatory lifetime and rapid hepatic clearance of IL-6 from the portal venous blood. In contrast to serum IL-6, acute-phase proteins, which have a longer circulatory lifetime, were significantly correlated with clinical activity indices. Only the follow-up of individual patients with initially highly active disease showed a further increase in IL-6 levels during acute exacerbations of the inflammatory process. The results show that most patients with even moderately active CD have significantly increased serum concentrations of IL-6, most probably reflecting a continuous stimulation of IL-6-producing cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370661     DOI: 10.1016/0016-5085(92)90098-j

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  84 in total

1.  Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.

Authors:  C Schulte; H Goebell; H D Röher; K M Schulte
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

2.  Specific targeting of IL-6 signalling pathway: a new way to treat IBD?

Authors:  P Desreumaux
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

3.  Expression of interleukin 6 in brain and colon of rats with TNBS-induced colitis.

Authors:  Kai Wang; Chuan-Ping Yuan; Wei Wang; Zhan-Qing Yang; Wei Cui; Lian-Zhi Mu; Zhan-Peng Yue; Xiu-Ling Yin; Zhong-Ming Hu; Ju-Xiong Liu
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 4.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 5.  Medical approaches and future options in chronic active ulcerative colitis.

Authors:  J T Siveke; C Folwaczny
Journal:  Int J Colorectal Dis       Date:  2004-01-15       Impact factor: 2.571

Review 6.  Averting inflammation by targeting the cytokine environment.

Authors:  Manfred Kopf; Martin F Bachmann; Benjamin J Marsland
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

7.  Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Authors:  Marla Cindy Dubinsky
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

8.  Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children.

Authors:  Andrew Sawczenko; Omeia Azooz; Joanna Paraszczuk; Maja Idestrom; Nick M Croft; Martin O Savage; Anne B Ballinger; Ian R Sanderson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

9.  Compromised neuroimmune status in rats with experimental colitis.

Authors:  Lysa Boissé; Marja D Van Sickle; Keith A Sharkey; Quentin J Pittman
Journal:  J Physiol       Date:  2003-03-14       Impact factor: 5.182

10.  Increased expression of long pentraxin PTX3 in inflammatory bowel diseases.

Authors:  Shingo Kato; Mitsuko Ochiai; Tomoya Sakurada; Shino Ohno; Kyoko Miyamoto; Mina Sagara; Masataka Ito; Kyoko Takeuchi; Junko Imaki; Kazuro Itoh; Koji Yakabi
Journal:  Dig Dis Sci       Date:  2007-11-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.